

| | Item No. | STROBE recommendation | Fulfilled |
|--|--|--|-----------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | Yes |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Yes |
| Introduction Background / rationale Objectives | 2 | Explain the scientific background and rationale for the investigation being reported | Yes |
| | 3 | State specific objectives, including any pre-specified hypotheses | Yes |
| Methods Study design Setting Participants Variables Data sources / measurement Bias Study size Quantitative variables Statistical methods | 4 | Present key elements of study design early in the paper | Yes |
| | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Yes |
| | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | Yes |
| | | (b) For matched studies, give matching criteria and number of exposed and unexposed | NA |
| | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Yes |
| | 8 ^a | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Yes |
| | 9 | Describe any efforts to address potential sources of bias | Yes |
| | 10 | Explain how the study size was arrived at | Yes |
| | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Yes |
| | 12 | (a) Describe all statistical methods, including those used to control for confounding | Yes |
| | | (b) Describe any methods used to examine subgroups and interactions | Yes |
| | | (c) Explain how missing data were addressed | Yes |
| (d) If applicable, explain how loss to follow-up was addressed | | Yes | |
| (e) Describe any sensitivity analyses | | NA | |
| Results Participants Descriptive data Outcome data Main results Other analyses | 13 ^a | (a) Report numbers of individuals at each stage of study - e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Yes |
| | | (b) Give reasons for non-participation at each stage | Yes |
| | | (c) Consider use of a flow diagram | Yes |
| | 14 ^a | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | Yes |
| | | (b) Indicate number of participants with missing data for each variable of interest | Yes |
| | | (c) Summarize follow-up time (e.g., average and total amount) | Yes |
| | 15 ^a 16 | Report numbers of outcome events or summary measures over time | Yes |
| (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | | Yes | |
| (b) Report category boundaries when continuous variables were categorized | | NA | |
| 17 | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA | |
| | Report other analyses done - e.g., analyses of subgroups and interactions, and sensitivity analyses | Yes | |
| Discussion Key results Limitations Interpretation Generalizability | 18 | Summarize key results with reference to study objectives | Yes |
| | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Yes |
| | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Yes |
| | 21 | Discuss the generalizability (external validity) of the study results | Yes |
| Other information Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Yes |

^aGive information separately for exposed and unexposed groups